

**RECEIVED  
CENTRAL FAX CENTER**

**AUG 08 2005**

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/607,530	
	Filing Date	June 26, 2003	
	First Named Inventor	DUNNING, Laura et al.	
	Art Unit	1623	
	Examiner Name	Paul V. Ward	
Total Number of Pages in This Submission	3	Attorney Docket Number	53001AUSM1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks This response to restriction requirement is being submitted to the USPTO centralized facsimile number of (571) 273-3250. 8300.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	BERLEX BIOSCIENCES		
Signature			
Printed name	Jacqueline S. Larson		
Date	Aug. 8, 2005	Reg. No.	30,279

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:	
Signature	
Typed or printed name	Mary Ann Flores
Date	Aug 8, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Certificate of Transmission under 37 CFR 1.8  
I hereby certify that this correspondence is being facsimile transmitted to the  
Patent and Trademark Office's central facsimile number of (571) 273-8300 on  
Aug 8, 2005

  
Mary Ann Flores

Docket No. 53001AUSM1

RECEIVED  
CENTRAL FAX CENTER

AUG 08 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Laura DUNNING et al.

Serial No. 10/607,530

: Group Art Unit 1623

Filed 06/26/2003

: Examiner Paul V. WARD

For: SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS

Mail Stop NON-FEE AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**


In response to the restriction requirement mailed July 13, 2005, Applicants elect the invention of Group I, that is the compounds of Formula 1a/2a where  $n = 0$ , subject to the right to rejoin the non-elected method claims corresponding thereto under appropriate conditions. Applicants further reserve the right to file subsequent divisional applications on any non-elected subject matter.

~~Applicants wish to point out that the claims listed as falling under each of several~~  
of the Invention Groups are incorrect as stated in the Office Action of July 13. Specifically, claim 1 claims a method and not a compound. Thus, more correctly, Groups I-VII should be according to claim 8 rather than to claim 1, and Groups VIII-XIV should be according to claims 1 and 20-22.

Claims 8-19 read on the elected invention.

Applicants elect the following species for search purposes:

Docket No. 53001AUSM1



That is, a compound of formula 2a where n is zero, R<sup>1</sup> is amino, R<sup>2</sup> is halo, R<sup>3</sup> is hydrogen, R<sup>4</sup> is hydrogen, R<sup>5</sup> is -C(O)NHR<sup>9</sup>, and R<sup>9</sup> is optionally substituted heterocyclyl.

Upon allowance of a generic claim, Applicants respectfully request consideration of claims to additional species that include all the limitations of the allowed generic claim, as well as rejoinder of the method claims that include all the limitations of the allowed compound claims pursuant to MPEP §821.04 and In re Ochiai (37 USPQ 1127 (Fed. Cir. 1995)).

Respectfully submitted,

*Jacqueline S. Larson*

Jacqueline S. Larson  
Patent Attorney for Applicants  
Registration No. 30279

Date: Aug. 8, 2005

Berlex Pharmaceuticals  
Corporate Patents  
2600 Hilltop Drive  
P.O. Box 4099  
Richmond, California 94804-0099  
Telephone: (510)-669-4483  
Fax: (510)-262-7095  
Email: jackie\_larson@berlex.com